Loading company…
PaxMedica develops biopharmaceutical treatments for neurodevelopmental disorders.
PaxMedica is a clinical-stage biopharmaceutical company developing treatments for neurodevelopmental disorders, including PAX-101 and PAX-102 for autism spectrum disorder and fragile X-associated tremor or ataxia. The company is based in New York, US, and was founded in 2018 by Michael Derbyand. In November 2022, Lincoln Park Capital agreed to acquire the company for USD 20 million.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in